The Effect of Triflusal on Peripheral Microcirculation Dysfunction

Yonsei University

Status and phase

Completed

Phase 4

Conditions

Vasospastic Syndrome

Treatments

Drug: Aspirin

Drug: Triflusal

Study type

Interventional

Funder types

Other

Identifiers

NCT01612273

4-2011-0018

Details and patient eligibility

About

To explore the efficacy of triflusal in patients with symptomatic peripheral microcirculation dysfunction. Triflusal is a salicylate compound approved in several countries as antithrombotic agent and it additionally has vasodilatory effect. The hypothesis is to explore if there is a improvement of peripheral microcirculation by triflusal.

Enrollment

92 patients

Sex

All

Ages

40 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Between 40 and 70 years of age
Diagnosed vasospastic syndrome with nailfold capillaroscopy (Fingertip is subjected to carbon dioxide at -15°C for 60 seconds. People found to have a blood-flow standstill of at least 12s in one or more capillaries were defined as having vasospasticity)
More than seven points in 10-question interview provided by Nagashima et al.
Written informed consent

Exclusion criteria

Prior documented diabetes
Overt peripheral artery disease
Pregnant or nursing
bleeding tendency
Any contraindication of antiplatelet agent
Thrombocytopenia (platelet < 100,000mm3)
Chronic liver disease (ALT > 100 IU/L or AST > 100 IU/L) or renal dysfunction (creatinine > 4.0 mg/dl)
Patients who can not stop to take aspirin